SecBot SecBot
PRESS-RELEASE ·Filed Nov 11, 2026

ONCY

Oncolytics Biotech, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed5d 10h ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor for study initiation in Q1 2027 and any interim data readouts. The collaboration validates pelareorep's potential in HPV-associated cancers but provides no near-term revenue. Success could open a broader development path across HPV-positive tumors.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ONCY drug pipeline →

pelareorep

◆ Mixed Named in this press release
Impact
Phase
Phase 2/3
Time to market
At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
Next catalyst
None dated

What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.3720
T+0 close · Nov 11, 2026 · via day close
Latest settled
−0.54%
T+1 · $0.3700
Vs SPY
−0.17%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $0.3720entry
  2. T+1 · 4d ago −0.54%α −0.17% · $0.3700
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate its investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi) in a clinical study for patients with squamous cell anal carcinoma (SCAC) who have progressed on first-line therapy. The study is expected to begin in Q1 2027 at a U.S. cancer center, with Coherus supplying LOQTORZI. This is a non-financial collaboration that provides drug supply and supports a focused clinical evaluation in an indication with no approved second-line therapy.

Key Facts

  • Oncolytics entered a clinical supply agreement with Coherus Oncology for a study combining pelareorep and toripalimab in second-line SCAC patients.
  • The study is expected to begin in Q1 2027 at a premier U.S. cancer center.
  • No approved therapy exists for second-line SCAC patients.
  • Coherus will provide LOQTORZI (toripalimab-tpzi) to Oncolytics; no financial terms were disclosed.
  • Pelareorep has Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer.

Financial Impact

No financial terms disclosed; drug supply agreement only.

research and development expenses

Risk Factors

  • Clinical trial may fail to show efficacy in second-line SCAC patients.
  • No financial consideration disclosed; value depends entirely on clinical outcomes.
  • Study enrollment and timeline may be delayed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3401132

Track record

32 reports on ONCY

Performance horizon

3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  3. Nov 11, 20265d ago Press Release Neutral 3/10 Viewing Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  5. Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  7. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
  8. Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  9. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
  10. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 11, 2026